Brooks Laboratories Share Price

NSE
BROOKS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Brooks Laboratories
Brooks Laboratories Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Brooks Laboratories Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
32.65% Fall from 52W High
-12.2
Dividend yield 1yr %
0

Brooks Laboratories Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Brooks Laboratories Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
38.45 Cr
20.79 Cr
17.93 Cr
17.72 Cr
21.75 Cr

Brooks Laboratories Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021
80.44 Cr
63.41 Cr
91.99 Cr
77.98 Cr

Brooks Laboratories Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
0.7 Cr
0.96 Cr
-0.21 Cr
0.3 Cr
0.58 Cr

Brooks Laboratories Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021
1.53 Cr
-27.74 Cr
-19.31 Cr
-19.37 Cr
Brooks Laboratories Result Highlights
  • Brooks Laboratories Ltd reported a 83.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 76.0%.

  • Its expenses for the quarter were up by 88.8% QoQ and 77.6% YoY.

  • The net profit increased 15.4% QoQ and increased 17.8% YoY.

  • The earnings per share (EPS) of Brooks Laboratories Ltd declined at 1.8 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Brooks Laboratories shareholding Pattern

Promoter
52.6%
Mutual Funds
9.9%
Domestic Institutions
10.4%
Public
37%
Promoter
59.1%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
37.1%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.5%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%

Brooks Laboratories Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
8
Bearish Moving Averages
8
5Day EMA
137.70
10Day EMA
136.40
12Day EMA
135.30
20Day EMA
131.60
26Day EMA
130.00
50Day EMA
129.80
100Day EMA
133.30
200Day EMA
131.60
5Day SMA
139.90
10Day SMA
139.30
20Day SMA
129.40
30Day SMA
123.20
50Day SMA
121.40
100Day SMA
141.90
150Day SMA
142.00
200Day SMA
134.70
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
12800 Rs
12800 Rs
Week Rs
21270 Rs
21270 Rs
Month Rs
33331 Rs
69739 Rs
Resistance & Support
135.05
Pivot
Resistance
First Resistance
136.89
Second Resistance
139.85
Third Resistance
141.69
Support
First Support
132.09
Second support
130.25
Third Support
127.29
Relative Strength Index
53.38
Money Flow Index
72.38
MACD
5.39
MACD Signal
4.70
Average True Range
9.42
Average Directional Index
21.16
Rate of Change (21)
19.84
Rate of Change (125)
-4.66

Brooks Laboratories Latest News

29 APR 2025 | Tuesday

Brooks Laboratories Ltd - 533543 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

19 APR 2025 | Saturday

Brooks Laboratories Ltd - 533543 - Intimation Of Update In Registrar And Transfer Agent (RTA) Contact Details

11 APR 2025 | Friday

Brooks Laboratories Ltd - 533543 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

View More

Brooks Laboratories Company background

Founded in: 2002
Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. Brooks Laboratories is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a worlds largest dedicated EU certified plant at Vadodara.In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (RD) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal Rajesh Mahajan.In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS IAF.In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.On 7 March 2017, Brooks Laboratories world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line.The Company started production and sales at its manufacturing facility in Vadodara in 201920.
Read More

Brooks Laboratories FAQs

Brooks Laboratories share price is ₹133.94 in NSE and ₹132.15 in BSE as on 29/4/2025.

Brooks Laboratories share price in the past 1-year return was 25.41. The Brooks Laboratories share hit a 1-year low of Rs. 73.25 and a 1-year high of Rs. 198.86.

The market cap of Brooks Laboratories is Rs. 394.55 Cr. as of 29/4/2025.

The PE ratios of Brooks Laboratories is 222.08 as of 29/4/2025.

The PB ratios of Brooks Laboratories is 3.39 as of 29/4/2025

The Mutual Fund Shareholding in Brooks Laboratories was 9.9% at the end of 29/4/2025.

You can easily buy Brooks Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Brooks Laboratories stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -